Cardiff Oncology, Inc. (CRDF) Form 8-K — Oct 27, 2026
$CRDFForm 8-KItems 5.02, 5.03, 7.01, 9.01Filed Oct 27, 2026, 4:44 PM ET0001493152-26-048720Original filing
Cardiff Oncology (CRDF) disclosed that Chief Medical Officer Dr. Roger Sidhu separated from the company on October 22, 2026, in a mutually agreed transition, and appointed Dr. Leila Alland as interim CMO effective October 23, 2026 under a consulting agreement paying $35,000 per month through April 22, 2027. Dr.
Key figures
- Agreement end date
- April 22, 2027 (or completion of services, extendable)
- Interim cmo monthly fee
- 35000
- Authorized common shares
- 300000000
- Authorized preferred shares
- 20000000
- Interim cmo time commitment
- up to 50% of professional time
- Patients on treatment months
- more than 18 months
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.